Takeda Ventures, Inc. is a venture capital arm of Takeda Pharmaceutical Company Limited specializing direct and fund of fund investing. Within direct investing firm specializes in seed; start up, early stage, mid stage, and mid venture capital investments, though it will consider product, target and technology opportunities at any stage. Within fund of fund investing firm specializes in venture capital funds. It may also consider follow-on rounds of investment. The firm does not invest in gene therapy or anti-infective products, medical devices, or diagnostics devices. It seeks to focus its investments in the therapeutics, including, pharmaceutical sector, in drugs and bio therapeutics with a focus on cardiovascular (heart failure, peripheral artery disease, etc.), chronic inflammatory and immune disorders (rheumatoid arthritis, systemic lupus erythematous, psoriasis, COPD and asthma), central nervous system (specifically Alzheimer's disease and schizophrenia), metabolic disorders (obesity, diabetes, and dyslipidemias), gastroenterology (inflammatory bowel disease, irritable bowel syndrome and fibrosis/cirrhosis), renal/urological disease (chronic kidney disease, acute kidney injury, etc.) oncology therapeutic domains, regenerative medicines (excluding cell therapy), novel vaccines technologies, RNA and DNA modulation, and innovative protein and peptide bio therapeutics. The firm also facilitates preclinical therapeutic discovery alliances. It typically invests in the United States, Canada, and Europe. The firm seeks to invest between $0.25 million and $5 million. It prefers to co-invest as a minority stake holder, holding less than 15% equity interest, with venture capital firms, private equity funds, angels, or institutional investors as lead investors. The firm prefers to act as a board observer in its portfolio companies. Takeda Ventures, Inc. was founded in November 2001 and is based in Palo Alto, California with additional offices in San Diego, California; Cambridge, the United Kingdom and Hersliya, Israel.